Recombinant Human Cytochrome P450 2D6 (CYP2D6)

1. prevalence of CYP2D6*4 1934AA genotype was higher in total HIV patients compared to healthy controls; similarly, CYP2D6*4 1934AA genotype was much more prevalent in HIV patients without hepatotoxicity compared to healthy controls; there was no significant difference in genotype or allele frequencies of CYP2D6*4 1934G/A polymorphism between the patients with hepatotoxicity and those without or healthy controls PMID: 30357957
2. CYP2D6 polymorphisms increase vulnerability to tramadol-induced hepatotoxicity. PMID: 29555325
3. Hot flash severity during tamoxifen therapy can not be accounted for by CYP2D6 genotype or observed plasma concentration of tamoxifen, 4-hydroxytamoxifen, or endoxifen PMID: 29980881
4. found a novel haplotype which involves 100C>T without 4180G>C PMID: 28606035
5. There was a significant difference in baseline neuropsychological scores among schizophrenia patients with three genotypes of CYP2D6 rs1135840. Also, rs1135840 showed a significant association with change in scores after risperidone treatment. This reflected a smaller change in GG genotype than C allele carriers; comparison of these two genotype groups gave a significant difference. PMID: 28131599
6. The ratio dehydro-aripiprazole/aripiprazole was influenced by CYP2D6 phenotype PMID: 29325225
7. In a cohort of schizophrenia inpatients CYP2D6 metabolic activity affects mean AP daily dose only in the presence of DRD2 Taq1A polymorphic allele. CYP2D6 metabolic activity correlates independently from DRD2 Taq1A polymorphism with hospital stay duration. Subpopulation of schizophrenia inpatients with altered CYP2D6 activity (PMs and UMs) carriers of Taq1A polymorphisms needs special attention of clinicians in aligning o PMID: 29930225
8. Dacomitinib total (AUCinf) and peak exposures (Cmax) were similar among subjects with different CYP2D6 genotypes. PMID: 28648122
9. CYP2D6*4 Polymorphism is associated with drug resistance in Breast Cancer. PMID: 29479969
10. Comparisons of pharmacokinetics of 25 substrates CYP2C9, CYP2C19, or CYP2D6 in healthy Chinese and European subjects (classified with same enzyme activity) suggest that, for most substrates, limited interethnic pharmacokinetic differences exist (according to the databases used in this study). (CYP2C9 = cytochrome P450 family 2 subfamily C member 9; CYP2C19 = cytochrome P450 family 2 subfamily C member 19) PMID: 29181698
11. TAM metabolism is extremely complex and involves several drug-metabolizing enzymes. Despite having shown a clear gene-exposure effect, CYP2D6 genotype can only partially explain the interindividual variability observed in TAM metabolite levels. PMID: 27698402
12. CYP2D6 polymorphisms were not associated with hypertension risk. PMID: 29549925
13. Results found significant association of C2850T, G1846A and C100T polymorphisms of CYP2D6 with coronary artery disease especially in females of North-West Indian population. PMID: 29660517
14. This population-based study does not support the hypothesis that patients with diminished CYP2D6 activity achieve inferior tamoxifen benefit. These contradictory findings suggest that the association between CYP2D6 genotype and tamoxifen treatment efficacy is null or near null, and unlikely to be useful in clinical practice. PMID: 28730340
15. The study results indicated the good response pattern was influenced by the concentration of donepezil, but not by APOE and CYP2D6 polymorphisms. PMID: 27716659
16. tamoxifen biotransformation to endoxifen is highly dependent on CYP2D6 activity; however, it is unclear whether there is an association between CYP2D6 genotype or endoxifen concentration and tamoxifen efficacy. PMID: 27249031
17. even though the available recommendations are against the CYP2D6 screening, the negative results of clinical trials may have been biased by issues in data collection, analysis and interpretation. PMID: 27883289
18. CYP2D6 protein and activity levels did not differ significantly between the genotypes (CYP2D6*1/*1, *1/*10, and *10/*10 genotypes) in the small intestine of the Japanese population. PMID: 28626197
19. genetic association studies in Chinese population: Data suggest that genetic polymorphisms and mutations in CYP2D6 are associated with alterations in metabolism of the anti-hemangioma medication hemangeol; some genetic alterations exclude hemangeol as a substrate for CYP2D6. PMID: 26542054
20. Genetic polymorphisms of some CYP enzymes, especially CYP2D6*10, could affect enzyme activity in hepatocellular carcinoma PMID: 27203676
21. This study demonstrates that the GSTP1*B and *C allelic variants may be considered a candidate gene for AD[Alzheimer disease]. It can be suggested that although CYP2D6*4 polymorphism is not a risk of AD[Alzheimer disease], the CYP2D6*4 and GSTP1 polymorphism may interact with beta-HCH, dieldrin, and copper to influence the risk of AD [Alzheimer disease]. PMID: 24584466
22. The number of functional CYP2D6 genes was positively associated with an increased risk of tardive dyskinesia, and suggest that this could be due to the generation of neurotoxic metabolites. PMID: 24595968
23. study found the 1846A allele frequency in Tatars was lower than in Russians, but the difference was not statistically significant; a statistically significant association between the development of extrapyramidal disorders (EPD) during haloperidol monotherapy and heterozygous 1846GA genotype and 1846A allele frequency was revealed among all schizophrenic patients and among those of Tatar ethnicity PMID: 27875318
24. The loss of function CYP2D6*3 (g.2549delA, rs35742686) genetic variant was found and contained the CYP2D6 g.2470T>C (rs17002852) variation, which had an allele frequency of 2.47%. PMID: 29073588
25. The CYP2D6 genotype may be potentially effective for predicting the response to donepezil treatment in Alzheimer's Disease patients. PMID: 27282366
26. We exploited CYP2D6 allele-frequency data that have been compiled for Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines .This comprehensive study summarizes allele frequencies, diplotypes, and predicted phenotype across major populations, providing a rich data resource for clinicians and researchers. Challenges of phenotype prediction from genotype data are highlighted and discussed. PMID: 27388693
27. In utero exposure to opioids is associated with increased DNA methylation of ABCB1, CYP2D6, and OPRM1 opioid-related genes in the newborn infant. PMID: 28867064
28. A total of 72 single nucleotide polymorphisms were identified. CYP2D6*1, *2, *4, *5, *10,*41, and duplication of the gene were found in the Orang Asli, whereby CYP2D6*2 and *41 alleles are reported for the first time in the Malaysian population PMID: 28525288
29. Data suggest that expression of CYP2D6 in hepatocytes is repressed by MIRN370 (hsa-miR-370-3p); MIRN370 represses expression of CYP2D6 even under the influence of CYP2D6 inducer (the glucocorticoid dexamethasone); the mechanism appears to involve the facilitation of CYP2D6 mRNA degradation. (CYP2D6 = cytochrome P450 family 2 subfamily D member 6; MIRN370 = microRNA 370) PMID: 28552654
30. Report predicted and measured CYP2D6 phenotype in a diverse South African population. PMID: 26503815
31. No association between cytochrome P450 CYP2D6 ultra-rapid metabolizer status and attempted suicide was observed in bivariate PMID: 27463022
32. Studied frequency of ADRB1 Arginine389Glycine (Arg389Gly) and Cytochrome p450 2D6*10 (Cyp2D6*10) polymorphism in cases of heart failure-reduced ejection fraction (HFREF), and to evaluate the influence of the polymorphisms in response to beta-blocker (BB) therapy; found a statistically significant association was observed with CC genotype and Glisin-Glisin (GG) genotype. PMID: 27665326
33. Variant genotypes of CYP2D6 are associated with an increased risk of esophageal squamous cell carcinoma in Kashmir, India. PMID: 28368717
34. genetic variation in CYP2D6 is a key predictor for the response to tamoxifen in patients with breast cancer PMID: 27797974
35. These results indicated that most of the allelic variants of CYP2D6 studied here, exhibited significantly decreased enzymatic activities towards methadone N-demethylation. PMID: 26968424
36. Evaluation of CYP2D6 ultrarapid metabolism should take into account activity of the multiplied alleles to avoid potential misclassification. PMID: 27272044
37. Of 830 patients with sickle cell disease, 621 (75%) had a CYP2D6 genotype result; 7.1% were ultra-rapid or possible ultra-rapid metabolizers, and 1.4% were poor metabolizers. PMID: 27335380
38. The purpose of this study was to determine the magnitude of effect of CYP2D6 genotype (activity score) on the dose-exposure relationship for ATX and its metabolites in children and adolescents with ADHD. PMID: 26660002
39. The kinetic parameters Km , Vmax and intrinsic clearance (Vmax /Km ) of N-desmethyltamoxifen were determined using CYP2D6 variants found in Chinese Han population. PMID: 27109434
40. present data in vitro suggest that the newly found variants significantly reduced catalytic activities compared with CYP2D6.1; given that CYP2D6 protein activities could affect carvedilol plasma levels, these findings are greatly relevant to personalized medicine PMID: 27354764
41. this meta-analysis shows that CYP2D6 gene polymorphisms are associated with susceptibility to autoimmune diseases in Caucasians PMID: 27749127
42. CYP2D6 polymorphisms were associated with decreased rates of pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine. PMID: 27253829
43. CYP2D6(*)10 mutations affect the pharmacokinetics of iloperidone and its metabolites in Chinese schizophrenia patients, suggesting that the clinical doses of iloperidone for patients with CYP2D6(*)10 mutations need to be optimized. PMID: 27665849
44. This study assess the catalytic activities of 24 CYP2D6 alleles variants toward tolterodine in vitro. There are 8 variants which showed altered catalytic activity toward tolterodine. PMID: 28087463
45. CYP2D6 polymorphisms were associated with the formation of O-desmethyl gefitinib from gefitinib. PMID: 27154635
46. allele were found to be related to the susceptibility to organophosphate chronic toxicity in Egyptians. PMID: 26723569
47. Olanzapine clearance was not affected by CYP2D6 or FMO3 genotypes or smoking behavior as a single factor under the present conditions because olanzapine clearance is mediated by multiple enzymes involved in two major and one minor pathways PMID: 26856397
48. Individual differences in metabolic clearance of risperidone under the present conditions were not significantly influenced by the genotypes of CYP2D6 or CYP3A5 PMID: 26856541
49. The multiplex SNaPshot method allows for specific and accurate detection of CYP2D6 genotypes and ADRB1 genotypes and haplotypes. This platform is simple and efficient and suited for high throughput. PMID: 27108086
50. CYP2D6 variants affect bufuralol and dextromethorphan in a Chinese population PMID: 26310775

显示更多

收起更多

HGNC: 2625

OMIM: 124030

KEGG: hsa:1565

STRING: 9606.ENSP00000353820

UniGene: Hs.648256